Description
Recombinant Mouse PD-L1/B7-H1/CD274 Protein (His Tag) (Active) | PKSM040919 | Gentaur US, UK & Europe Disrtribition
Synonyms: A530045L16Rik Protein, Mouse;B7h1 Protein, Mouse;Pdcd1l1 Protein, Mouse;Pdcd1lg1 Protein, Mouse;Pdl1 Protein, Mouse
Active Protein: Active protein
Activity: A DNA sequence encoding the mouse CD274 (NP_068693.1) extracellular domain (Met 1-Thr 238) was fused with a polyhistidine tag at the C-terminus.
Protein Construction: A DNA sequence encoding the mouse CD274 (NP_068693.1) extracellular domain (Met 1-Thr 238) was fused with a polyhistidine tag at the C-terminus.
Fusion Tag: C-His
Species: Mouse
Expressed Host: HEK293 Cells
Shipping: This product is provided as lyophilized powder which is shipped with ice packs.
Purity: > 98 % as determined by reducing SDS-PAGE.
Endotoxin: < 1.0 EU per μg of the protein as determined by the LAL method.
Stability and Storage: Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80℃. Reconstituted protein solution can be stored at 4-8℃ for 2-7 days. Aliquots of reconstituted samples are stable at < -20℃ for 3 months.
Molecular Mass: 26.3 kDa
Formulation: Lyophilized from sterile PBS, pH 7.4
Reconstitution: Please refer to the printed manual for detailed information.
Background: Programmed death-1 ligand-1 (PD-L1, CD274, B7-H1) has been identified as the ligand for the immunoinhibitory receptor programmed death-1(PD1/PDCD1) and has been demonstrated to play a role in the regulation of immune responses and peripheral tolerance. PD-L1/B7-H1 is a member of the growing B7 family of immune molecules and this protein contains one V-like and one C-like Ig domain within the extracellular domain, and together with PD-L2, are two ligands for PD1 which belongs to the CD28/CTLA4 family expressed on activated lymphoid cells. By binding to PD1 on activated T-cells and B-cells, PD-L1 may inhibit ongoing T-cell responses by inducing apoptosis and arresting cell-cycle progression. Accordingly, it leads to growth of immunogenic tumor growth by increasing apoptosis of antigen specific T cells and may contribute to immune evasion by cancers. PD-L1 thus is regarded as promising therapeutic target for human autoimmune disease and malignant cancers.Immune CheckpointImmune Checkpoint Blockade: Blocking Antibodies Immune Checkpoint Blockade: PD-L1 / B7-H1 / CD274 Blocking AntibodiesImmune Checkpoint Detection: Antibodies Immune Checkpoint Detection: ELISA Antibodies Immune Checkpoint Detection: IHC Antibodies Immune Checkpoint Detection: ICC Antibodies Immune Checkpoint Detection: FCM Antibodies Immune Checkpoint Detection: WB AntibodiesImmune Checkpoint Proteins PD-L1 / B7-H1 / CD274 Immune Checkpoint ProteinsImmune Checkpoint Targets Co-inhibitory Immune Checkpoint Targets Immunotherapy Cancer Immunotherapy Targeted Therapy
Research Area: N/A
